ERAS Stock Discussion
Erasca, Inc Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acute Myeloid Leukemia Colorectal Cancer Enzymes Tyrosine Kinase Receptors Oncogenes NSCLC Non Small Cell Lung Carcinoma Metastatic Solid Tumors Ras Gtpase Bemcentinib Ptpn11
Recent Comments
- LillyMilly1 on LILM
- LillyMilly1 on LILM
- TraderMike on RYDE what a RIDE!!! Holy Crap!
- Crunching_The_Market on RYDE what a RIDE!!! Holy Crap!
- LillyMilly1 on LILM
From the Blog
Popular Now
Featured Articles